The American Diabetes Association (ADA) has updated its standards of care to reflect the growing role of diabetes technology in improving patient outcomes. Key updates include expanded recommendations for continuous glucose monitoring (CGM) for both patients with type 1 diabetes and patients with type 2 diabetes on non-insulin therapies. This includes its use in pregnant individuals with diabetes to help achieve glycemic and A1C goals. The ADA stresses an individualized approach to device selection based on each patient’s needs, preferences, and skills, highlighting the importance of tailored, patient-centric care.

Additionally, the ADA emphasizes the need for comprehensive education and ongoing support for patients using diabetes technologies like CGMs and insulin pumps. Ensuring access to these tools across all ages and A1C levels, regardless of insurance or financial status, is a central recommendation to promote equity in diabetes care. Standardized reporting methods, such as ambulatory glucose profiles, are encouraged to streamline decision-making. Overall, these updates highlight the essential role of diabetes technology in modern care, with a focus on personalized, accessible, and effective management strategies for better patient outcomes.

Reference: Danatech Staff. 5 Key Diabetes Tech Takeaways from ADA’s Updated Standards of Care. Danatech. Published January 6, 2025. Accessed February 26, 2025. https://www.adces.org/education/danatech/latest-news/danatech-latest-news/2025/01/06/5-key-diabetes-tech-takeaways-from-ada’s-updated-standards-of-care